Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

Sponsor

Zhejiang Cancer Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05461690

Collaborator

Sun Yat-sen University (Other), Hunan Cancer Hospital (Other), Fujian Cancer Hospital (Other), Zhejiang University (Other), Taizhou Hospital of Zhejiang Province (Other)

Enrollment

Arm

33.9

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The incidence of homologous recombination deficiency in metastatic triple negative breast cancer was 52%-59%，PARP plays a key role in sensing DNA damage and converting it into intracellular signals that activate the base excision repair (BER) and single-strand break repair pathways. Treatment with PARP inhibitors could represent a novel opportunity to selectively kill a subset of cancer cells with deficiencies in DNA repair pathways. This is a multicenter, single-arm, phase II study evaluating the efficacy and safety of niraparib in patients with HRD positive metastatic triple negative breast cancer.

Condition or Disease	Intervention/Treatment	Phase
Homologous Recombination Deficiency Triple Negative Breast Cancer	Drug: Niraparib	Phase 2

Detailed Description

Simon's two-stage optimization method is used to estimate the sample size. The first kind of error α Set to 0.1, type II error β Set to 0.25, P0 to 30%, P1 to 44%. 22 patients were enrolled in the first stage. If the number of effective cases ≤ 6, the trial was terminated. Otherwise, continue to enroll 26 patients in the second stage. If the number of effective cases in the two stages is ≤ 18, there is no need to further study the drug. Assuming an abscission rate of 5%, it is estimated that 50 subjects will be enrolled in the trial.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II Study of Niraparib Single Agent in Metastatic Triple Negative Breast Cancer Patients With Homologous Recombination Deficiency

Anticipated Study Start Date :

Sep 1, 2022

Anticipated Primary Completion Date :

Dec 31, 2024

Anticipated Study Completion Date :

Jun 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Niraparib group 200mg once a day for patients with body weight <77kg or baseline platelet count <150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.	Drug: Niraparib 200mg once a day for patients with body weight <77kg or baseline platelet count <150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first. Other Names: Zejula

Arm

Intervention/Treatment

Experimental: Niraparib group

200mg once a day for patients with body weight <77kg or baseline platelet count <150,000/µL, and 300mg once a day for patients with body weight ≥ 77kg and baseline platelet count ≥ 150,000/µL until disease progression or intolerable toxicity whichever occurs first.

Drug: Niraparib

Other Names:

Zejula

Outcome Measures

Primary Outcome Measures

Objective Response Rate (ORR) [From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.]
ORR is defined as the percentage of patients who achieved a best overall response of Complete Response (CR) or Partial Response (PR), per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions as assessed by the Investigator: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Secondary Outcome Measures

Progression-Free Survival (PFS) [From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.]
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.
Clinical Benefit Rate (CBR) [From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.]
Percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST v1.1.
Time to response (TTR) [From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months.]
TTR defined as the time from the date of the first dose of study treatment to the first objective tumor response when CR or PR is observed.
Overall survival (OS) [From date of first dose until the date of death from any cause, assessed up to 60 months.]
Time to death from any cause from the date of first dose of study treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient is female at least 18 years of age.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Life expectancy longer than 6 months.
Patients with histologically confirmed metastatic breast cancer must have disease that is HER2-negative, estrogen receptor-negative, and progesterone receptor-negative (ie, TNBC).
Patient has measurable lesions by RECIST v1.1.
Patients has archival tumor tissue available or a fresh biopsy must be obtained prior to study treatment initiation for HRD test. The HRD test results must be positive (HRR mutation or/and HRD score≥42).
Patients had received no more than two previous chemotherapy regimens for metastatic disease, and they had received neoadjuvant or adjuvant treatment or treatment for metastatic disease with an anthracycline (unless it was contraindicated) or a taxane.
Previous neoadjuvant or adjuvant treatment with platinum or/and anthracycline were allowed if at least 6 months had elapsed since the last dose. Previous treatment with platinum or/and anthracycline for metastatic disease were allowed if there was no evidence that disease progression had occurred during treatment.
Patient has adequate organ function, defined as:
Absolute neutrophil count (ANC) ≥ 1,500/μL(growth factor support treatment shall not be used within 7 days after the start of study treatment）
Platelets ≥ 100,000/μL(platelet transfusion or any form of platelet raising therapy shall not be used within 2 weeks after the start of the study)
Hemoglobin ≥ 9 g/dL(blood transfusion shall not be used within 2 weeks after the start of study treatment. EPO support treatment shall not be used within 7 days after the start of study treatment.)
Serum creatinine ≤ 1.5× upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min using Cockcroft-Gault equation for patients with creatinine levels > 1.5× institutional ULN
Total bilirubin ≤ 1.5× ULN OR direct bilirubin ≤ 1× ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN unless liver metastases are present, in which case they must be ≤ 5× ULN
Urine protein ≤ (+), or 24-hour urine protein quantity is less than 1g
International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
Activated partial thromboplastin time (aPTT) ≤ 1.5× ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Female patient has a negative serum pregnancy test within 7days prior to taking study medication if of childbearing potential, or agrees to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment, or be of non-childbearing potential. Non-childbearing potential is defined as (by other than medical reasons).
Female patients must agree not to breastfeed during the study period or within 180 days after the last dose of study treatment.
Patient agrees to blood samples during screening and at the end of treatment for cytogenetic analysis.

Exclusion Criteria:

Patients have received PARP inhibitors for metastatic breast cancer.
Patients who are concurrently participating in any interventional clinical trial and have received an investigational therapy ≤ 4 weeks prior to initiation of protocol therapy or within at least 5 elimination half-lives of the investigational drug.
Patients who have received radiotherapy with > 20% bone marrow coverage before treatment initiation, except for minor palliative radiotherapy within 1 weeks prior to enrollment.
Patients with visceral crisis requiring chemotherapy.
Patients with hypersensitivity to nilaparib.
Patients receiving blood transfusions (platelets or red blood cells) ≤ 4 weeks prior to starting protocol therapy.
Patients who have received colony-stimulating factors (eg, granulocyte-colony stimulating factor [g-CSF], granulocyte-macrophage colony-stimulating factor, or recombinant erythropoietin) 4 weeks prior to starting protocol therapy.
Known history of platelet transfusions for chemotherapy-induced thrombocytopenia or ≥ Grade 3 hematologic toxicity from prior cancer therapy (lasting > 4 weeks and associated with most recent therapy).
Patient has any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Patient has a serious, uncontrolled medical condition, non-malignant systemic disease, or active, uncontrolled infection.
Patient has other types of cancer ≤ 2 years prior to starting protocol therapy.
Patients with symptomatic brain metastasis or leptomeningeal metastasis.
Patients with prior allogeneic bone marrow transplant or cord blood transplant.
Patients who cannot swallow oral medication.
Patients with gastrointestinal disorders that could interfere with absorption of the study drug.
Patient has a systemic active autoimmune disease (use of disease modifying agents, corticosteroids, or immunosuppressive agents, etc.) within the past 2 years.
Patients with a history of human immunodeficiency virus, active hepatitis B or C.
Female patients who are pregnant or lactating or adults of childbearing potential not using effective contraceptive methods.